Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.71 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.71 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.71 |
| ▸ | PI4KA | P42356 | 3/20 | 0.65 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.65 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.65 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.65 |
| ▸ | NSD3 | Q9BZ95 | 5/20 | 0.59 |
| ▸ | NSD2 | O96028 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30289754 | 1.00 | ADORA2A (0.71) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL11008256 | 0.90 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL11222112 | 0.89 | ADORA2A (0.80) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL5016779 | 0.89 | ADORA2A (0.70) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL11012652 | 0.87 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL11010323 | 0.87 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL5033136 | 0.84 | ADORA2A (0.73) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL2638103 | 0.84 | ADORA2A (0.73) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL2638100 | 0.83 | ADORA2A (0.71) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL233405 | 0.83 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114044849-B | Cucurbituril supramolecular conductive hydrogel with toughness and viscosity and preparation method thereof | 山东大学 | 2023-03-10 | — | — | CN | claimed |
| CN-114044849-A | Cucurbituril supramolecular conductive hydrogel with toughness and viscosity and preparation method thereof | 山东大学 | 2022-02-15 | — | — | CN | claimed |
| CN-116942674-A | Use of purine derivatives as NSD2 and NSD3 inhibitors | 普美瑞(苏州)生物科技有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116903623-A | Purine derivative and application thereof | 普美瑞(苏州)生物科技有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116854772-A | Analogue of endomorphin and adenine conjugated peptide with analgesic activity and synthesis method thereof | 中国人民解放军空军军医大学 | 2023-10-10 | — | — | CN | disclosed |
| CN-114044849-B | Cucurbituril supramolecular conductive hydrogel with toughness and viscosity and preparation method thereof | 山东大学 | 2023-03-10 | — | — | CN | disclosed |
| CN-114044849-A | Cucurbituril supramolecular conductive hydrogel with toughness and viscosity and preparation method thereof | 山东大学 | 2022-02-15 | — | — | CN | disclosed |
| US-20180100036-A1 | CLICK NUCLEIC ACID POLYMERS AND METHODS OF USE | UNIV COLORADO REGENTS (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180100036-A1 | CLICK NUCLEIC ACID POLYMERS AND METHODS OF USE | UNIV COLORADO REGENTS (US) | 2018-04-12 | — | — | US | disclosed |
| US-8088758-B2 | 17β-hydroxysteroid dehydrogenase type I inhibitors | ABBOTT PRODUCTS GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| EP-1685150-B1 | NOVEL 17beta HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | SOLVAY PHARM GMBH (DE) | 2008-09-03 | — | — | EP | disclosed |
| US-20050192263-A1 | 3,15-substituted estrone compounds; treatment of steroid hormone dependent diseases such as breast cancer, colon cancer, endometriosis, benign prostatic hyperplasia | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-09-01 | — | — | US | disclosed |
| US-4542137-A | NONEXPLOSIVE, CARDIOVASCULAR | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 1985-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192263-A1 | 3,15-substituted estrone compounds; treatment of steroid hormone dependent diseases such as breast cancer, colon cancer, endometriosis, benign prostatic hyperplasia | HSD17B11, HSD17B1, HSD17B3 | ADORA2A 3889/4885ADORA1 2517/4885ADORA2B 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.